Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Wilkinson

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1990
Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancerM H Bronchud, J M Margison, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicityM P Decatris, P M Wilkinson, R S Welch, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 15, 2000
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphomaJ P Wylie, R A Cowan, J A Radford, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Trilostane in the treatment of advanced breast cancerC G Beardwell, A C Hindley, P M Wilkinson, et al.
Lancet (London, England)|May 8, 1982
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour GroupN Thatcher, P V Barber, R D Hunter, et al.
British Journal of Cancer|December 1, 1986
A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancerB Dhokia, P A Canney, D Pectasides, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPPM R Ranson, J A Radford, R Swindell, et al.
Blood|September 15, 1992
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialR Pettengell, H Gurney, J A Radford, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|January 1, 1990
Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancerM H Bronchud, J M Margison, A Howell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2000
High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicityM P Decatris, P M Wilkinson, R S Welch, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 15, 2000
A doxorubicin-based regimen used in the treatment of elderly patients with high-grade non-Hodgkin's lymphomaJ P Wylie, R A Cowan, J A Radford, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Trilostane in the treatment of advanced breast cancerC G Beardwell, A C Hindley, P M Wilkinson, et al.
Lancet (London, England)|May 8, 1982
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour GroupN Thatcher, P V Barber, R D Hunter, et al.
British Journal of Cancer|December 1, 1986
A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancerB Dhokia, P A Canney, D Pectasides, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1991
An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPPM R Ranson, J A Radford, R Swindell, et al.
Blood|September 15, 1992
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialR Pettengell, H Gurney, J A Radford, et al.
Pageof 8